AzurRx BioPharma Performance
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and AzurRx BioPharma are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days AzurRx BioPharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, AzurRx BioPharma is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Quick Ratio | 1.25 | |
| Fifty Two Week Low | 3.5700 | |
| Target High Price | 5.00 | |
| Fifty Two Week High | 26.3000 | |
| Target Low Price | 2.00 |
AzurRx |
AzurRx BioPharma Relative Risk vs. Return Landscape
If you would invest (100.00) in AzurRx BioPharma on October 12, 2025 and sell it today you would earn a total of 100.00 from holding AzurRx BioPharma or generate -100.0% return on investment over 90 days. AzurRx BioPharma is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than AzurRx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
AzurRx BioPharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AzurRx BioPharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AzurRx BioPharma, and traders can use it to determine the average amount a AzurRx BioPharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| AZRX |
Based on monthly moving average AzurRx BioPharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AzurRx BioPharma by adding AzurRx BioPharma to a well-diversified portfolio.
AzurRx BioPharma Fundamentals Growth
AzurRx Stock prices reflect investors' perceptions of the future prospects and financial health of AzurRx BioPharma, and AzurRx BioPharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AzurRx Stock performance.
| Return On Asset | -233.79 | |||
| Current Valuation | 50.95 M | |||
| Shares Outstanding | 78.58 M | |||
| Price To Earning | (1.99) X | |||
| Price To Book | 19.53 X | |||
| EBITDA | (38.05 M) | |||
| Cash And Equivalents | 8.07 M | |||
| Cash Per Share | 0.09 X | |||
| Total Debt | 543.81 K | |||
| Debt To Equity | 0.08 % | |||
| Book Value Per Share | 0.19 X | |||
| Cash Flow From Operations | (19.28 M) | |||
| Earnings Per Share | (1.87) X | |||
| Total Asset | 5.8 M | |||
| Retained Earnings | (64.34 M) | |||
| Current Asset | 1.51 M | |||
| Current Liabilities | 2.84 M |
Things to note about AzurRx BioPharma performance evaluation
Checking the ongoing alerts about AzurRx BioPharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AzurRx BioPharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AzurRx BioPharma is not yet fully synchronised with the market data | |
| AzurRx BioPharma has some characteristics of a very speculative penny stock | |
| AzurRx BioPharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (74.49 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| AzurRx BioPharma currently holds about 8.07 M in cash with (19.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09. |
- Analyzing AzurRx BioPharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AzurRx BioPharma's stock is overvalued or undervalued compared to its peers.
- Examining AzurRx BioPharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AzurRx BioPharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AzurRx BioPharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AzurRx BioPharma's stock. These opinions can provide insight into AzurRx BioPharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in AzurRx Stock
If you are still planning to invest in AzurRx BioPharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AzurRx BioPharma's history and understand the potential risks before investing.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |